Who are BCG Tokyo-172 Strain Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bacille Calmette Guerin (BCG), BCG Solution, Zoster Vaccine Live, RotaTeq™ (V260), Yellow fever vaccine, Institut Pasteur, Bacille Calmette-Guerin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bcg-tokyo-172-strain-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BCG Tokyo-172 Strain Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BCG Tokyo-172 Strain Vaccine (BCG Tokyo-172 Strain Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Oncology.

phase 3 Live attenuated vaccine Pattern recognition receptors (TLR2, TLR4, NOD2) Oncology Biologic Live · refreshed every 30 min

Target snapshot

BCG Tokyo-172 Strain Vaccine (BCG Tokyo-172 Strain Vaccine) — SWOG Cancer Research Network. BCG Tokyo-172 is a live attenuated Mycobacterium bovis vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BCG Tokyo-172 Strain Vaccine TARGET	BCG Tokyo-172 Strain Vaccine	SWOG Cancer Research Network	phase 3	Live attenuated vaccine	Pattern recognition receptors (TLR2, TLR4, NOD2)
Bacille Calmette Guerin (BCG)	Bacille Calmette Guerin (BCG)	Bandim Health Project	marketed	Live attenuated vaccine
BCG Solution	BCG Solution	Alliance for Clinical Trials in Oncology	marketed	Live attenuated vaccine / Immunotherapy
Zoster Vaccine Live	Zoster Vaccine Live	Merck Sharp & Dohme LLC	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
RotaTeq™ (V260)	RotaTeq™ (V260)	Merck Sharp & Dohme LLC	marketed	Live attenuated vaccine
Yellow fever vaccine, Institut Pasteur	Yellow fever vaccine, Institut Pasteur	University of Oxford	marketed	Live attenuated vaccine
Bacille Calmette-Guerin	Bacille Calmette-Guerin	Urological Oncology Council of Northern Tokyo	marketed	Live attenuated vaccine / Immunotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BCG Tokyo-172 Strain Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/bcg-tokyo-172-strain-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab